These studies have led us to posit that IDH1 mutations are tumor-suppressive on the contrary; the biological consequence of IDH1 mutations in glioma is to ameliorate patient survival, at least in part, by inhibiting oncogenic signaling [13]. The gene discussed is IDH1; the disease is central nervous system cancer.